Carl J. Danzig, MD | Image Credit: Rand Eye Institute A recent study reaffirmed the safety and efficacy of using faricimab to treat macular edema due to retinal vein occlusion (RVO) by reducing vascular endothelial growth factor (VEGF). The study was a secondary phase of the BALATON and COMINO trials, which met their primary endpoints … Read more
Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined in an early benefit assessment whether faricimab offers patients benefits over ranibizumab or aflibercept. However, the … Read more
Faricimab Treatment for Macular Oedema: IQWiG Finds Lack of Added Benefit The German Institute for Quality and Efficiency in Health Care (IQWiG) has recently assessed the benefits of faricimab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. This follows its approval in Europe in July 2024. However, the evaluation concluded … Read more
Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined in an early benefit assessment whether faricimab offers patients benefits over ranibizumab or aflibercept. However, the … Read more